Biohaven doses first subject in Phase I/II tumour treatment study [Yahoo! Finance]
Biohaven Ltd. Common Shares (BHVN)
Last biohaven ltd. common shares earnings: 2/25 04:45 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.biohavenpharma.com
Company Research
Source: Yahoo! Finance
It is a first-in-human, multicentre, open-label trial structured into two segments: a Phase I dose escalation and a multicohort Phase II dose expansion. The initial phase will focus on determining the safety and tolerability of BHV-1510, establishing the recommended doses for expansion (RDEs), and identifying the maximum-tolerated dose (MTD), if applicable. The subsequent phase will evaluate the preliminary efficacy of the drug in signal-finding expansion cohorts. BHV-1510 features a homogeneous drug-antibody ratio (DAR) of four and employs a Trop-2-directed antibody linked to a Topoisomerase 1 (TopoIx) payload. The ADC employs a unique site-specific conjugation method and a highly stable and irreversible linker developed by GeneQuantum Healthcare. Preclinical studies have demonstrated that BHV-1510 delivers cellular cytotoxicity, bystander killing, and immunogenic cell death, potentially leading to enhanced monotherapy efficacy and synergistic effects along with anti-PD-1
Show less
Read more
Impact Snapshot
Event Time:
BHVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BHVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BHVN alerts
High impacting Biohaven Ltd. Common Shares news events
Weekly update
A roundup of the hottest topics
BHVN
News
- Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at Bank of America Co. from $52.00 to $62.00. They now have a "buy" rating on the stock.MarketBeat
- Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at Sanford C. Bernstein from $55.00 to $66.00. They now have an "outperform" rating on the stock.MarketBeat
- BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal [Yahoo! Finance]Yahoo! Finance
- Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at Royal Bank of Canada from $59.00 to $68.00. They now have an "outperform" rating on the stock.MarketBeat
BHVN
Earnings
- 8/8/24 - Miss
BHVN
Sec Filings
- 9/25/24 - Form 4
- 9/23/24 - Form 8-K
- 8/16/24 - Form 8-K
- BHVN's page on the SEC website